# Research on YTS109 Cell in Patients With Recurrent/Refractory Autoimmune Hemolytic Anemia

> **NCT07453836** · PHASE1 · NOT_YET_RECRUITING · sponsor: **China Immunotech (Beijing) Biotechnology Co., Ltd.** · enrollment: 13 (estimated)

## Conditions studied

- Autoimmune Hemolytic Anemia

## Interventions

- **DRUG:** YTS109 cell

## Key facts

- **NCT ID:** NCT07453836
- **Lead sponsor:** China Immunotech (Beijing) Biotechnology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03-18
- **Primary completion:** 2027-03-18
- **Final completion:** 2028-03-18
- **Target enrollment:** 13 (ESTIMATED)
- **Last updated:** 2026-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07453836

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07453836, "Research on YTS109 Cell in Patients With Recurrent/Refractory Autoimmune Hemolytic Anemia". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT07453836. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*